A Phase 3 Multi-center Randomized Open-Label Study of Carbavance (Meropenem/PRX7009) Versus Best Available Therapy in Subjects with Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Clinical Trial Grant
Administered By
Medicine, Infectious Diseases
Awarded By
Rempex Pharmaceuticals
Start Date
December 15, 2014
End Date
December 14, 2017
Administered By
Medicine, Infectious Diseases
Awarded By
Rempex Pharmaceuticals
Start Date
December 15, 2014
End Date
December 14, 2017